Bullish
Pfizer's stock rises 1.3% to $24.35 amid FDA approval for new breast cancer indication.
Pfizer's stock increased by 1.3% to $24.35 on July 7, 2026, following FDA approval of IBRANCE for a new breast cancer indication. Despite this positive development, the stock remains below its 50-day and 200-day moving averages, indicating potential investor caution.
Key points
- FDA approves IBRANCE for new breast cancer indication, potentially boosting sales.
- Stock trading below key moving averages suggests cautious investor sentiment.
- Analysts maintain a consensus 'Hold' rating with a price target of $28.59.
Sources
AI-generated from public news sources. Not financial advice.
